secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALX ONCOLOGY HOLDINGS INC (ALXO)
CIK:        0001810182
Form:       8-K
Filed at:   2021-12-17T23:59:59+00:00
Accession:  0001193125-21-361275
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ALX Oncology enters $150M at-the-market stock offering agreement
----------------------------------------------------------------

- Entered Sales Agreement with Cantor Fitzgerald and Credit Suisse for ATM offering of up to $150M in common stock.
- Sales may be made at-the-market on Nasdaq or in negotiated transactions; company sets parameters per placement notice.
- Sales Agents receive 3.0% commission per share sold; company not obligated to sell any shares.
- Offering made under existing S-3 shelf registration (filed August 2021); prospectus supplement filed December 17, 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810182/000119312521361275/0001193125-21-361275-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810182/000119312521361275/d227281d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-361275

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer